AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00644293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin (Zithromax)
Description: azithromycin 500 mg tablet by mouth once daily for 3 days
Study NCT00644293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT00644293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin SR
Description: azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
Study NCT04404855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NGS + Antibiotic Recommendation
Description: NGS results in addition to recommended antibiotic therapy made by infectious disease pharmacist
Study NCT04404855 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care treatment
Description: Subjects will have a standard of care urine culture and prophylactic antibiotic prescribed per routine care.
Study NCT02064010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNC-102
Description: Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks
Study NCT02064010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, administered orally for 4 weeks
Study NCT01424423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01424423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1223249
Description: I.V. Infusion
Study NCT01148511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Ranibizumab was supplied as a sterile solution in sealed glass vials.
Study NCT01148511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5 mg
Description: Ranibizumab was supplied as a sterile solution in sealed glass vials.
Study NCT00860782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Educational Support
Description: Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
Study NCT01544751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose metformin
Description: 500 mg twice a day
Study NCT01544751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg twice a day
Study NCT01544751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 20 mg/day
Study NCT02474108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical prevention of atrial fibrillation
Description: Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.
Study NCT02474108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cardiomonitor
Description: in both groups cardiac rhythm will be controlled by a cardiomonitor
Study NCT02474108 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cardiomonitor
Description: in both groups cardiac rhythm will be controlled by a cardiomonitor
Study NCT02242708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternative nostril breathing
Description: The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
Study NCT02466555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
Study NCT00763165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan
Description: Brush twice daily
Study NCT00763165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily
Study NCT00763165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily
Study NCT02690610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS TBNA of mediastinal lesions or lymph nodes
Description: Through endo-bronchial ultrasound, a transbronchial needle will be introduced to take biopsies from mediastinal lesions under ultrasonic guidance.
Study NCT00395850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Disulfiram
Description: Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
Study NCT00395850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
Study NCT04790292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group M
Description: 10mg morphine in 5ml normal saline + 10ml of 0.25% bupivacaine ( total volume 15 ml) were injected intra-articularly
Study NCT04790292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group MD
Description: 10mg morphine + 8mg dexamethasone completed to 5 ml with normal saline + 10 ml of 0.25% bupivacaine (total volume of 15ml) were injected intra-articularly
Study NCT00804934 — intervention group
Intervention type: DRUG
Intervention: Lucentis
Description: 0.5mg Lucentis every four months
Study NCT03973762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DR Grading with CAD
Description: A CAD system is used to make DR grading.
Study NCT03973762 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DR Grading by expert panel
Description: DR Grading by expert panel
Study NCT01177566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus
Description: pimecrolimus 1% cream twice daily
Study NCT01177566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: topical medical device
Description: Eletone cream three times daily
Study NCT01867463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Euvax B
Description: Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.
Study NCT03424174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coated Total Knee Arthroplasty
Description: Implantation coated Total Knee Arthroplasty
Study NCT04028518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-PA
Description: Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time.
Study NCT04028518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-PA
Description: Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time.
Study NCT03424174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Total Knee Arthroplasty
Description: Implantation StandardTotal Knee Arthroplasty
Study NCT03642717 — intervention group
Intervention type: DRUG
Intervention: JARDIANCE DUO®
Description: empagliflozin and metformin
Study NCT04028518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase for Injection
Description: Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h.
Study NCT02536534 — intervention group
Intervention type: OTHER
Intervention: Correlation assessment
Study NCT00274287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM CSF
Description: 250 ug/m2 daily for 2 weeks followed by 2 weeks of rest
Study NCT04964037 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04117659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: withdrawal of oral medication (phosphodiesterase-5 inhibitor) in pretreated patients
Description: discontinuation of the oral medication with a phosphodiesterase-5 inhibitor
Study NCT01789593 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: glucose clamp
Description: Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
Study NCT04432909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The level of CNV
Description: The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. And the patient will be followed for up to 2 years.
Study NCT01274000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral
Study NCT00642668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: 1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
Study NCT03387163 — intervention group
Intervention type: DRUG
Intervention: Sacubitril/Valsartan
Description: commercially available Sacubitril/Valsartan: 24/26; 49/51 ; 97/103
Study NCT00256698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection 250 mg loading dose (LD) regimen
Study NCT00256698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg oral tablet
Study NCT00256698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg oral tablet
Study NCT03745092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: normobaric oxygen
Description: Normobaric oxygen (NBO) is a routine adjuvant hyperoxygenation intervention supplied by facemask (such as Venturi mask), with one atmosphere pressure (1ATA=101.325kPa).
Study NCT03745092 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: room air
Description: The patient had a rest with lying, sitting or walking, did not performed with NBO intervention.
Study NCT04255355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic alignment and forceful expiration
Description: The participant will be in supine with feet flat on a wall and the knees and hips flexed to 90 degrees. A standard 5 ball will be placed between the knees. The participant will hold a standard 9-inch balloon in the mouth with one hand. The subject will be instructed to isometrically contract the hamstrings to lift the ischium off the table while maintaining a posterior pelvic tilt. In this position, subject will be instructed to perform isometric hip adduction by squeezing the ball placed between the knees. The subject will then be instructed to breathe in through the nose and blow the air out into the balloon with full exhalation to activate the transverse and oblique abdominals. The participant will hold the breath for 3 seconds while maintaining hamstring contraction, adductor contraction, and transverse and oblique abdominal contraction. This process will be repeated four times. This exercise will be performed once daily under the supervision of the therapist for 5 days.
Study NCT04255355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic repositioning exercise
Description: The participant will be positioned supine with their feet flat on a wall and the knees and hips flexed to 90 degrees. The subject will be instructed to isometrically contract the hamstrings to allow the ischial tuberosities to lift off the table while also maintaining a posterior pelvic tilt. The tailbone should be slightly lifted off the table, the abdominal muscles should be relaxed, and the low back should be flat on the table. While maintaining the posterior pelvic tilt, the subject will be instructed to perform isometric hip adduction by squeezing the ball that is placed between the knees. The subject will hold for 3 seconds and then relax. This process will be repeated four times. This exercise will be performed daily under the supervision of the therapist for 5 days.
Study NCT04255355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercise
Description: For diaphragmatic breathing exercise, the subject will be in supine position. The investigator places both hands around the participant's lower ribs and abdominal area. The investigator applies slight manual resistance to the chest and abdominal wall during inhalation phase of breathing.The participant is instructed to apply outward pressure against the investigator resistance and to raise the chest and abdominal wall simultaneously with inhalation. Then participants performs a full exhalation and hold his/her breath for 3 seconds before breathing in again. This process is repeated for 4 breathing cycles. Participants will perform this exercise once a day under investigator supervision.
Study NCT00945581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Nutritional Powder Formula
Description: Powder twice a day
Study NCT00945581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Powder twice a day
Study NCT02576028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation® (FM)
Description: Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation
Study NCT02576028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard active exercises
Description: two sessions of 45 minutes of active exercises
Study NCT02576028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard active exercises
Description: two sessions of 45 minutes of active exercises
Study NCT03465332 — intervention group
Intervention type: OTHER
Intervention: Doctor's questionnaire
Description: The survey of physicians will be performed using doctor's questionnaire, which will be developed by lung specialists who are not participating in the survey.
Study NCT03465332 — intervention group
Intervention type: OTHER
Intervention: Subject file
Description: All subject-based data will be obtained by retrospective evaluation of subject files available at the treating lung specialist.
Study NCT02620514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Reminders
Description: Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.
Study NCT02620514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Visit
Description: Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
Study NCT03311347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: +Gz accelerations and positive pressure breathing
Study NCT02445066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D3
Study NCT01274000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study NCT02206607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 IR MST
Description: Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
Study NCT02620514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Educational Visit
Description: Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.
Study NCT02620514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Support
Description: Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
Study NCT00713336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: ZD4054 10mg Tablet
Study NCT00713336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD4054
Description: ZD4054 10mg Tablet
Study NCT00713336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZD4054
Description: ZD4054 10mg Tablet
Study NCT00713336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg capsule
Study NCT00713336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD4054 Placebo
Description: 3 tablets
Study NCT02206607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 MR 1
Description: Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
Study NCT02206607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 MR 2
Description: Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
Study NCT02206607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 MR 3
Description: Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
Study NCT03424187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chickpea
Description: all three meals are isocaloric but different in the chickpea structure( physical form):~• Whole chickpea, flour chickpea, intact cell flour chickpea
Study NCT00074607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Schedule~Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).~In the absence of disease progression or DLT, patients may proceed to consolidation.~Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.~Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year.
Study NCT03196518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: PET/CT study immediately after injection
Study NCT03196518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-tetrafluoroborate (18F-TFB)
Description: administration of a single dose of approximately 5-10 mCi 18F-TFB (mass \<= 50 μg) for imaging purposes
Study NCT02077374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Description: 25 mg BID for 28 days
Study NCT02077374 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID for 28 Days
Study NCT02875704 — intervention group
Intervention type: OTHER
Intervention: Anterior Chamber (AC) Tap
Description: Aqueous Samples will be collected for measurement of biomarkers
Study NCT00470418 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NIC5-15
Description: a natural product, found in many foods and plants with mild insulin sensitizing effects
Study NCT00713336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZD4054 Placebo
Description: 3 tablets
Study NCT00713336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: 1 capsule
Study NCT00470418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator